Potassium and Ventricular Arrhythmias

Definition

Plasma potassium level exerts a direct effect on cardiac excitability and arrhythmia susceptibility via its role in setting resting membrane potential and repolarization kinetics. Both hypokalemia and low-normal potassium (3.5–4.0 mmol/L) increase ventricular arrhythmia risk in structurally abnormal hearts, while high-normal levels (4.5–5.0 mmol/L) are associated with lower mortality. The POTCAST trial (2025) was the first large RCT to demonstrate that actively targeting high-normal potassium reduces the burden of malignant ventricular arrhythmias and adverse outcomes in ICD patients.

Key Concepts

Electrophysiological Basis of Hypokalemia-Driven Arrhythmia

• Low plasma potassium reduces IK1 (inward rectifier) and IKr (rapid delayed rectifier) currents, prolonging action potential duration (APD) and the QT interval — increasing dispersion of repolarization and risk of early afterdepolarizations (EADs) and triggered activity
• Hypokalemia also induces membrane depolarization instability and reduces the excitation threshold, facilitating reentrant circuits on a background of structural heart disease
• The U-shaped relationship between plasma potassium and mortality in cardiovascular disease has a nadir around 4.5 mmol/L — lower values (even within the "normal" 3.5–4.0 range) carry incremental risk (sources/potcast-nejm-2025, rating: very high)

POTCAST Trial — First Large RCT of Potassium Targeting

• Design: N=1,200; ICD patients; baseline K ≤4.3 mmol/L; randomized to targeting K 4.5–5.0 mmol/L (KCl tablets, MRA, dietary guidance, diuretic reduction) vs standard care; median 39.6 months; Denmark; open-label; event-driven
• Primary composite (sustained VT, appropriate ICD therapy, unplanned arrhythmia/HF hospitalization, or all-cause death): 22.7% vs 29.2%; HR 0.76 (95% CI 0.61–0.95; P=0.01; NNT=12.3) (sources/potcast-nejm-2025, rating: very high)
• Appropriate ICD therapy/documented VT: HR 0.75 (0.57–0.98) — 25% relative reduction
• Hospitalization for cardiac arrhythmia: HR 0.63 (0.42–0.93) — 37% relative reduction
• All-cause death and HF hospitalization: numerically lower (HR 0.85 and 0.64 respectively) but not statistically significant as individual endpoints
• NNT = 12.3 to prevent one composite event over ~3.3 years — a highly favorable absolute risk reduction for a low-cost, widely available intervention

Mechanism: Avoidance of Low-Normal Potassium, Not Achievement of High-Normal

• Only 249/600 (41.5%) of intervention patients reached the target range of 4.5–5.0 mmol/L; mean potassium rose only ~0.3 mmol/L (4.01 → 4.36 mmol/L)
• Benefit was present in those who did NOT achieve the target range (HR 0.70; 0.53–0.92) but not in those who did (HR 0.84; 0.63–1.12, NS)
• Interpretation: the primary mechanism is prevention of low-normal or intermittent hypokalemic episodes, not the specific achievement of 4.5–5.0 mmol/L (sources/potcast-nejm-2025, rating: very high)
• Clinically relevant implication: partial treatment (tolerable dose, modest K rise) still confers meaningful protection

Implication for MRA Mechanism in HF Landmark Trials

• In RALES (spironolactone, n=1,663), EPHESUS (eplerenone, post-MI HF, n=6,632), EMPHASIS-HF (eplerenone mild HF, n=2,737), and FINEARTS-HF (finerenone, HFpEF, n=6,001), the MRA-induced serum potassium rise of 0.1–0.3 mmol/L was historically viewed as a safety concern, not a therapeutic mechanism
• POTCAST finds benefit of comparable magnitude (~0.3 mmol/L rise) independent of whether MRAs were used — MRA subgroup HR 0.75 vs non-MRA subgroup HR 0.77 (overlapping CIs, no interaction)
• This raises the hypothesis that part of the mortality benefit in prior HF MRA trials was attributable to the potassium-raising effect rather than exclusively to aldosterone blockade (sources/potcast-nejm-2025, rating: very high)
• Similarly, beta-blockers and RAAS inhibitors (ACEi/ARB) also raise potassium; their cardioprotective benefit may partially derive from the same mechanism

Applicability and Safety

• Intervention is low-cost and available in all healthcare settings
• eGFR ≥30 required — patients with advanced CKD (eGFR <30) were excluded due to hyperkalemia risk
• Hyperkalemia hospitalizations were numerically higher (7 vs 2) but the overall electrolyte/renal hospitalization composite was not significantly different (HR 1.75; 95% CI 0.80–3.82)
• Creatinine rise was statistically significant but small (+4.11 μmol/L; P=0.002)
• 75.2% adherence to trial regimen through end of trial — feasible in clinical practice

Contradictions / Open Questions

• Target range not achieved in 58% of intervention patients — yet benefit observed: The trial cannot determine whether achieving the full 4.5–5.0 mmol/L target would produce a larger benefit, a smaller benefit, or carry additional hyperkalemia risk. The dose-response relationship between potassium level and arrhythmia reduction is not formally established. (sources/potcast-nejm-2025, rating: very high)
• MRA vs non-MRA mechanism not fully separated: The non-MRA subgroup (191 patients; HR 0.77; 0.56–1.00) had wide confidence intervals and the trial was not powered to test this interaction formally. It remains plausible that MRA-specific mechanisms (aldosterone blockade, anti-fibrotic effects) contribute independently of potassium. (sources/potcast-nejm-2025, rating: very high)
• All-cause mortality not significantly reduced: Despite significant composite endpoint reduction, individual all-cause mortality was HR 0.85 (NS). This likely reflects insufficient power (75 total deaths) and the fact that VT/ICD therapy events are far more common than death, driving the composite without necessarily translating to a mortality signal in this trial duration. (sources/potcast-nejm-2025, rating: very high)
• Applicability to non-ICD high-risk patients unknown: The trial exclusively enrolled ICD patients; patients at high arrhythmic risk without an ICD (e.g., high-risk HCM, Brugada syndrome, genetic channelopathies) were not studied. Extrapolation is plausible but unproven.
• Generalizability beyond Denmark: Single-country trial; dietary potassium intake baseline, genetic population differences, and guideline adherence in background GDMT may differ across health systems.

Connections

• Related to entities/ICD — trial population; appropriate ICD therapy as primary endpoint component
• Related to entities/Mineralocorticoid-Receptor-Antagonists — one mechanism to raise potassium; POTCAST raises hypothesis that K-raising, not exclusively aldosterone blockade, explains part of MRA benefit in HF
• Related to concepts/Cardiac-Action-Potential — electrophysiological basis (IKr/IK1 effects of hypokalemia; APD prolongation; EAD risk)
• Related to concepts/Cardiac-Repolarization — potassium directly modulates repolarization reserve and QT interval
• Related to concepts/ST-T-Changes — hypokalemia ECG pattern (U waves, T flattening, apparent QT prolongation)
• Related to concepts/Electrical-Storm — extreme end of ventricular arrhythmia burden spectrum
• Related to concepts/Bidirectional-Ventricular-Tachycardia — context of disease-specific arrhythmia triggered by low potassium (especially CPVT)

Sources

• sources/potcast-nejm-2025 — POTCAST RCT; HR 0.76 primary composite; first RCT of potassium targeting in ICD patients (rating: very high)